CODX: Co-Diagnostics, Inc. Stock

by  •  • Comments Off on CODX: Co-Diagnostics, Inc. Stock

SIC 3841 – Surgical and Medical Instruments and Apparatus

Valuation
Market Cap ($M) 11.78
Enterprise Value ($M) 8.85
Book Value ($M) 54.31
Book Value / Share 1.62
Price / Book 0.22
NCAV ($M) 22.60
NCAV / Share 0.67
Price / NCAV 0.52

Profitability (mra)
Return on Invested Capital (ROIC) -0.67
Return on Assets (ROA) -0.43
Return on Equity (ROE) -0.48

Liquidity (mrq)
Quick Ratio 4.27
Current Ratio 4.41

Balance Sheet (mrq) ($M)
Current Assets 32.29
Assets 64.00
Liabilities 9.69
Debt n/a
Equity n/a

Income Statement (mra) ($M)
Revenue 3.92
Operating Income -40.08
Net Income -37.64
Earnings Per Share Basic And Diluted n/a

Cash Flow Statement (mra) ($M)
Cash From Operations -29.16
Cash from Investing 17.07
Cash from Financing 0.10

(click for more detail)
Top 13F Investors Shares
(1000)		 Change
(%)		 Value
($1000)		 Change
(%)

(click for more detail)

Date Insider Trades Code Shares Value

(click for more detail)

File Date Form SEC Filings
2025-03-27 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549. Form 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2024 ☐ TRANSITION REPORT PURSU
2024-11-07 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2024 ☐ TRANSITION REPORT PURSUANT T
2024-08-08 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2024 ☐ TRANSITION REPORT PURSUANT TO SEC
2024-05-09 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2024 ☐ TRANSITION REPORT PURSUANT TO SE

(click for more detail)
Short Volume
Market Date Short Volume Total Volume Short Volume Ratio
2025-05-02 5,074 45,653 11.11
2025-04-30 78,045 295,332 26.43
2025-04-29 38,294 114,112 33.56
2025-04-28 61,126 282,207 21.66

(click for more detail)

Similar Companies
CHEK – Check-Cap Ltd. CLPT – ClearPoint Neuro, Inc.
COCH – Envoy Medical, Inc. CTSO – Cytosorbents Corporation
DCTH – Delcath Systems, Inc.


Financial data and stock pages provided by
Fintel.io